Literature DB >> 23148179

Current concepts in graves' disease.

Christian M Girgis1, Bernard L Champion, Jack R Wall.   

Abstract

Graves' disease is the most common cause of hyperthyroidism in the developed world. It is caused by an immune defect in genetically susceptible individuals in whom the production of unique antibodies results in thyroid hormone excess and glandular hyperplasia. When unrecognized, Graves' disease impacts negatively on quality of life and poses serious risks of psychosis, tachyarrhythmia and cardiac failure. Beyond the thyroid, Graves' disease has diverse soft-tissue effects that reflect its systemic autoimmune nature. Thyroid eye disease is the most common of these manifestations and is important to recognise given its risk to vision and potential to deteriorate in response to radioactive iodine ablation. In this review we discuss the investigation and management of Graves' disease, the recent controversy regarding the hepatotoxicity of propylthiouracil and the emergence of novel small-molecule thyroid-stimulating hormone (TSH) receptor ligands as potential targets in the treatment of Graves' disease.

Entities:  

Keywords:  Graves' disease; autoimmune thyroid disease; hyperthyroidism; neomercazole; propylthiouracil; radioactive iodine; thionamides; thyroid eye disease; thyroidectomy

Year:  2011        PMID： 23148179      PMCID： PMC3474632          DOI： 10.1177/2042018811408488

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN： 2042-0188            Impact factor:   3.565


  47 in total

1.  Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States.

Authors:  L Wartofsky; D Glinoer; B Solomon; S Nagataki; R Lagasse; Y Nagayama; M Izumi
Journal:  Thyroid       Date:  1991       Impact factor: 6.568

2.  Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis.

Authors:  P Vitti; T Rago; S Mazzeo; S Brogioni; M Lampis; A De Liperi; C Bartolozzi; A Pinchera; E Martino
Journal:  J Endocrinol Invest       Date:  1995-12       Impact factor: 4.256

3.  Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study.

Authors:  B M Dobyns; G E Sheline; J B Workman; E A Tompkins; W M McConahey; D V Becker
Journal:  J Clin Endocrinol Metab       Date:  1974-06       Impact factor: 5.958

4.  Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole.

Authors:  D M Arab; D A Malatjalian; R S Rittmaster
Journal:  J Clin Endocrinol Metab       Date:  1995-04       Impact factor: 5.958

5.  Orbital Graves' disease. A modification of the "NO SPECS" classification.

Authors:  H J Van Dyk
Journal:  Ophthalmology       Date:  1981-06       Impact factor: 12.079

6.  Endocrine and metabolic emergencies: thyroid storm.

Authors:  Richard Carroll; Glenn Matfin
Journal:  Ther Adv Endocrinol Metab       Date:  2010-06       Impact factor: 3.565

7.  Antithyroid peroxidase autoantibodies in thyroid diseases.

Authors:  S Mariotti; P Caturegli; P Piccolo; G Barbesino; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

8.  The genetics of Graves' disease: HLA and disease susceptibility.

Authors:  V Stenszky; L Kozma; C Balázs; S Rochlitz; J C Bear; N R Farid
Journal:  J Clin Endocrinol Metab       Date:  1985-10       Impact factor: 5.958

9.  Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study.

Authors:  H Peters; C Fischer; U Bogner; C Reiners; H Schleusener
Journal:  Eur J Clin Invest       Date:  1996-01       Impact factor: 4.686

10.  Radioiodine treatment of Graves' disease. An assessment of its potential risks.

Authors:  G D Graham; K D Burman
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391
View more
  17 in total

1.  Outcomes After Urgent Thyroidectomy Following Rapid Control of Thyrotoxicosis in Graves' Disease are Similar to Those After Elective Surgery in Well-Controlled Disease.

Authors:  Adibah Ali; Miguel Debono; Sabapathy P Balasubramanian
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

2.  Dual thyroid ectopia with graves' disease: a case report and a review of the literature.

Authors:  Teik Hin Tan; Boon Nang Lee; Siti Zarina Amir Hassan; Ewe Seng Ch'ng; Zanariah Hussein
Journal:  Nucl Med Mol Imaging       Date:  2012-08-09

3.  Lipid peroxidation, proteins modifications, anti-oxidant enzymes activities and selenium deficiency in the plasma of hashitoxicosis patients.

Authors:  Malek Mseddi; Riadh Ben Mansour; Fatma Mnif; Bochra Gargouri; Mohamed Abid; Fadhel Guermazi; Hamadi Attia; Saloua Lassoued
Journal:  Ther Adv Endocrinol Metab       Date:  2015-10       Impact factor: 3.565

4.  [Clinical practice guidelines for acute and chronic thyroiditis (excluding autoimmune thyroiditis)].

Authors:  E A Troshina; E A Panfilova; M S Mikhina; I V Kim; E S Senyushkina; A A Glibka; B M Shifman; A A Larina; M S Sheremeta; M V Degtyarev; P O Rumyanstsev; N S Kuznetzov; G A Melnichenko; I I Dedov
Journal:  Probl Endokrinol (Mosk)       Date:  2021-04-12

5.  Single nucleotide polymorphism 1623 A/G (rs180195) in the promoter of the Thyroglobulin gene is associated with autoimmune thyroid disease but not with thyroid ophthalmopathy.

Authors:  Hooshang Lahooti; Senarath Edirimanne; John P Walsh; Leigh Delbridge; Emily J Hibbert; Jack R Wall
Journal:  Clin Ophthalmol       Date:  2017-07-25

6.  Epidemiology, management and outcomes of Graves' disease-real life data.

Authors:  Y S Hussain; J C Hookham; A Allahabadia; S P Balasubramanian
Journal:  Endocrine       Date:  2017-05-06       Impact factor: 3.633

7.  [Student abuse and Graves-basedow's disease: about a case].

Authors:  Marie-Pierrette Ntyonga-Pono; Daniela Nsame
Journal:  Pan Afr Med J       Date:  2017-01-12

8.  Novel single-nucleotide polymorphisms in the calsequestrin-1 gene are associated with Graves' ophthalmopathy and Hashimoto's thyroiditis.

Authors:  Hooshang Lahooti; Daniele Cultrone; Senarath Edirimanne; John P Walsh; Leigh Delbridge; Patrick Cregan; Bernard Champion; Jack R Wall
Journal:  Clin Ophthalmol       Date:  2015-09-18

Review 9.  Does autoimmunity against thyroglobulin play a role in the pathogenesis of Graves' ophthalmopathy: a review.

Authors:  Thayalini Shanmuganathan; Christian Girgis; Hooshang Lahooti; Bernard Champion; Jack R Wall
Journal:  Clin Ophthalmol       Date:  2015-12-03

10.  Thrombotic thrombocytopenic purpura possibly triggered by Graves' disease.

Authors:  Saurabh D Chitnis; Tuoyo O Mene-Afejuku; Amandeep Aujla; Ahmed Shady; Gaby S Gil; Eder Hans Cativo; Andrea Popescu-Martinez
Journal:  Oxf Med Case Reports       Date:  2017-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.